Abstract
Purpose
Quality of life (QoL) is frequently impaired in patients suffering from malignant disease. Disturbed metabolism of neurotransmitter serotonin might be crucially involved, and serotonin-precursor tryptophan is degraded during pro-inflammatory immune response. In this study, we compared QoL and fatigue self-rating scores of patients with various types of malignancy with tryptophan metabolic changes and immune activation status.
Methods
Venous blood was collected from 146 patients with gastrointestinal tumors (n = 43), hematological malignancy (n = 40), gynecological neoplasms (n = 26), lung cancer (n = 20) and from tumors of other localization (n = 17).
Results
QoL was significantly reduced in patients suffering from progressive tumor disease in comparison to stable or remitting disease, also feeling of fatigue was increased (both P < 0.001). Serum tryptophan concentrations were lower in patients with progressive disease (P < 0.01), and decreased tryptophan concentrations were related to decreased QoL (r s = 0.256, P < 0.01) and increased fatigue (r s = −0.179; P < 0.05). Concentrations of tryptophan and kynurenine and the kynurenine to tryptophan ratio were predictive for impaired QoL and increased fatigue in univariate regression analysis, in multivariate analysis higher ESR and neopterin concentration in combination with stage of disease predicted QoL deterioration.
Conclusions
Results suggest that immune-mediated tryptophan degradation may contribute to cancer-induced QoL deterioration.
Similar content being viewed by others
References
Allen-Mersh TG, Glover C, Fordy C, Henderson DC, Davies M (1998) Relation between depression and circulating immune products in patients with advanced colorectal cancer. J R Soc Med 91:408–413
Bower J E, Ganz P A, Aziz N, Fahey JL (2002) Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64:604–611
Brown RR, Ozaki Y, Datta S P, Borden EC, Sondel PM, Malone DG (1991) Implications of interferon-induced tryptophan catabolism in cancer auto-immune diseases and AIDS. Adv Exp Med Biol 294:425–435
Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ (2001) Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26:797–808
Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH (2003) Interferon-alpha-induced changes in tryptophan metabolism relationship to depression and paroxetine treatment. Biol Psychiatry 54:906–914
Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC (1989) Interferons and indoleamine 2 3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 45:535–541
Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Lee BN (2003) Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97:2919–2925
Cruess DG, Petitto JM, Leserman J, Douglas SD, Gettes DR, Ten Have TR, Evans DL. (2003) Depression and HIV infection: impact on immune function and disease progression. CNS Spectr 8:52–58
Dantzer R, Bluthe RM, Gheusi G, Cremona S, Laye S, Parnet P, Kelley KW (1998) Molecular basis of sickness behaviour. Ann NY Acad Sci 856:132–138
Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H (1990) Correlation between neopterin interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol 44:186–189
Denz H, Orth B, Weiss G, Herrmann R, Huber P, Wachter H, Fuchs D (1993) Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Investig 71:37–41
Dimeo F, Schmittel A, Fietz T, Schwartz S, Kohler P, Boning D, Thiel E (2004) Physical performance depression immune status and fatigue in patients with hematological malignancies after treatment. Ann Oncol 15:1237–1242
Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG (1996) Relation between tumor size quality of life and survival in patients with colorectal liver metastases. J Clin Oncol 14:171–175
Fuchs D, Moeller AA, Reibnegger G, Werner ER, Werner-Felmayer G, Dierich MP, Wachter H (1991) Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett 28:207–211
Giusti RM, Maloney EM, Hanchard B, Morgan OS, Steinberg SM, Wachter H, Williams E, Cranston B, Fuchs D, Manns A (1996) Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis and adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prev 5:699–704
Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG (2002) Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 86:1691–1696
Iwagaki H, Hizuta A, Tanaka N, Orita K (1995) Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin. Immunol Invest 24:467–478
Iwagaki H, Hizuta A, Uomoto M, Takeuchi Y, Saito S, Tanaka N (1997) Cancer cachexia and depressive states: a neuro-endocrine-immunological disease? Acta Med Okayama 51:233–236
Kronberger P, Weiss G, Tschmelitsch J, Fuchs D, Salzer GM, Wachter H, Reibnegger G (1995) Predictive value of urinary neopterin in patients with lung cancer. Eur J Clin Chem Clin Biochem 33:831–837
Kurzrock R (2001) The role of cytokines in cancer-related fatigue. Cancer 92:1684–1688
Lewenhaupt A, Ekman P, Eneroth P, Eriksson A, Nilsson B, Nordstrom L (1986) Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur Urol 12:422–425
Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4:250–255
Murr C, Bergant A, Widschwendter M, Heim K, Schrocksnadel H, Fuchs D (1999) Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem 45:1998–2004
Murr C, Widner B, Sperner-Unterweger B, Ledochowski M, Schubert C, Fuchs D (2000) Immune reaction links disease progression in cancer patients with depression. Med Hypotheses 55:137–140
Myint AM, Kim YK (2003) Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 61:519–525
Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310:850–855
Reibnegger G J, Bichler A H, Dapunt O, Fuchs DN, Fuith LC, Hausen A, Hetzel HM, Lutz H, Werner ER, Wachter H (1986) Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 46:950–955
Reibnegger G, Hetzel H, Fuchs D, Fuith LC, Hausen A, Werner ER, Wachter H (1987) Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 47:4977–4981
Schroecksnadel K, Winkler C, Fuith L C, Fuchs D (2005) Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 223:323–299
Taylor MW, Feng GS (1991) Relationship between interferon-gamma indoleamine 2 3-dioxygenase and tryptophan catabolism. FASEB J 5:2516–2522
UICC (1997) TNM-Klassifikation maligner Tumoren 5th edition Wittekind CH, Wagner G (eds) Springer, Berlin
Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274
Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G (1993) Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 53:260–265
Werner E R, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Wachter H (1989) Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2 3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J 262:861–866
Widner B, Werner ER, Schennach H, Wachter H, Fuchs D (1997) Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 43:2424–2426
Widner B, Sepp N, Kowald E, Ortner U, Wirleitner B, Fritsch P, Baier-Bitterlich G, Fuchs D (2000) Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 201:621–630
Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D (2002) Neopterin production tryptophan degradation and mental depression—what is the link? Brain Behav Immun 16:590–595
Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D (2003) Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 10:1581–1591
Acknowledgment
This work was supported by the “Stiftung Propter Homines, Vaduz -Fürstentum Liechtenstein”, by the government of the State of the Austrian Tyrol, and by the European Community, Project #019031 BAMOD “Austrian Cancer Society/Tyrol”. We thank Miss Astrid Haara for excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schroecksnadel, K., Fiegl, M., Prassl, K. et al. Diminished quality of life in patients with cancer correlates with tryptophan degradation. J Cancer Res Clin Oncol 133, 477–485 (2007). https://doi.org/10.1007/s00432-007-0191-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-007-0191-3